Report Cover

Global Recombinant Human Granulocyte Colony-Stimulating Market Research Report 2022


The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
    Lenograstim (Granocyte)
    Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
    Others
Segment by Application
    Chemotherapy Induced Neutropenia
    Before Blood Donation
    Stem Cell Transplants
    Others
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        U.A.E
By Company
    Amgen
    Qilu Pharmaceutical
    Shijiazhuang Pharmaceutical
    Kyowa Hakko Kirin
    Gensci
    Amoytop Biotech
    Hangzhou Jiuyuan
    Huaxin
    Triprime
    Sinovac
    Zhaoke
    Kawin
1 Recombinant Human Granulocyte Colony-Stimulating Market Overview
    1.1 Product Overview and Scope of Recombinant Human Granulocyte Colony-Stimulating
    1.2 Recombinant Human Granulocyte Colony-Stimulating Segment by Type
        1.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 Lenograstim (Granocyte)
        1.2.3 Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
        1.2.4 Others
    1.3 Recombinant Human Granulocyte Colony-Stimulating Segment by Application
        1.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Comparison by Application: (2022-2028)
        1.3.2 Chemotherapy Induced Neutropenia
        1.3.3 Before Blood Donation
        1.3.4 Stem Cell Transplants
        1.3.5 Others
    1.4 Global Recombinant Human Granulocyte Colony-Stimulating Market Size Estimates and Forecasts
        1.4.1 Global Recombinant Human Granulocyte Colony-Stimulating Revenue 2017-2028
        1.4.2 Global Recombinant Human Granulocyte Colony-Stimulating Sales 2017-2028
        1.4.3 Recombinant Human Granulocyte Colony-Stimulating Market Size by Region: 2017 Versus 2021 Versus 2028
2 Recombinant Human Granulocyte Colony-Stimulating Market Competition by Manufacturers
    2.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Recombinant Human Granulocyte Colony-Stimulating Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Recombinant Human Granulocyte Colony-Stimulating Manufacturing Sites, Area Served, Product Type
    2.5 Recombinant Human Granulocyte Colony-Stimulating Market Competitive Situation and Trends
        2.5.1 Recombinant Human Granulocyte Colony-Stimulating Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Recombinant Human Granulocyte Colony-Stimulating Players Market Share by Revenue
        2.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Granulocyte Colony-Stimulating Retrospective Market Scenario by Region
    3.1 Global Recombinant Human Granulocyte Colony-Stimulating Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Recombinant Human Granulocyte Colony-Stimulating Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures by Country
        3.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales by Country
        3.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures by Country
        3.4.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country
        3.4.2 Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures by Region
        3.5.1 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Region
        3.5.2 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures by Country
        3.6.1 Latin America Recombinant Human Granulocyte Colony-Stimulating Sales by Country
        3.6.2 Latin America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Market Facts & Figures by Country
        3.7.1 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Country
        3.7.2 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 U.A.E
4 Global Recombinant Human Granulocyte Colony-Stimulating Historic Market Analysis by Type
    4.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2017-2022)
    4.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2017-2022)
    4.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2017-2022)
5 Global Recombinant Human Granulocyte Colony-Stimulating Historic Market Analysis by Application
    5.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2022)
    5.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application (2017-2022)
    5.3 Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Amgen
        6.1.1 Amgen Corporation Information
        6.1.2 Amgen Description and Business Overview
        6.1.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.1.5 Amgen Recent Developments/Updates
    6.2 Qilu Pharmaceutical
        6.2.1 Qilu Pharmaceutical Corporation Information
        6.2.2 Qilu Pharmaceutical Description and Business Overview
        6.2.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.2.5 Qilu Pharmaceutical Recent Developments/Updates
    6.3 Shijiazhuang Pharmaceutical
        6.3.1 Shijiazhuang Pharmaceutical Corporation Information
        6.3.2 Shijiazhuang Pharmaceutical Description and Business Overview
        6.3.3 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.3.5 Shijiazhuang Pharmaceutical Recent Developments/Updates
    6.4 Kyowa Hakko Kirin
        6.4.1 Kyowa Hakko Kirin Corporation Information
        6.4.2 Kyowa Hakko Kirin Description and Business Overview
        6.4.3 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.4.5 Kyowa Hakko Kirin Recent Developments/Updates
    6.5 Gensci
        6.5.1 Gensci Corporation Information
        6.5.2 Gensci Description and Business Overview
        6.5.3 Gensci Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Gensci Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.5.5 Gensci Recent Developments/Updates
    6.6 Amoytop Biotech
        6.6.1 Amoytop Biotech Corporation Information
        6.6.2 Amoytop Biotech Description and Business Overview
        6.6.3 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.6.5 Amoytop Biotech Recent Developments/Updates
    6.7 Hangzhou Jiuyuan
        6.6.1 Hangzhou Jiuyuan Corporation Information
        6.6.2 Hangzhou Jiuyuan Description and Business Overview
        6.6.3 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.7.5 Hangzhou Jiuyuan Recent Developments/Updates
    6.8 Huaxin
        6.8.1 Huaxin Corporation Information
        6.8.2 Huaxin Description and Business Overview
        6.8.3 Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Huaxin Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.8.5 Huaxin Recent Developments/Updates
    6.9 Triprime
        6.9.1 Triprime Corporation Information
        6.9.2 Triprime Description and Business Overview
        6.9.3 Triprime Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Triprime Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.9.5 Triprime Recent Developments/Updates
    6.10 Sinovac
        6.10.1 Sinovac Corporation Information
        6.10.2 Sinovac Description and Business Overview
        6.10.3 Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Sinovac Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.10.5 Sinovac Recent Developments/Updates
    6.11 Zhaoke
        6.11.1 Zhaoke Corporation Information
        6.11.2 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Description and Business Overview
        6.11.3 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.11.5 Zhaoke Recent Developments/Updates
    6.12 Kawin
        6.12.1 Kawin Corporation Information
        6.12.2 Kawin Recombinant Human Granulocyte Colony-Stimulating Description and Business Overview
        6.12.3 Kawin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Kawin Recombinant Human Granulocyte Colony-Stimulating Product Portfolio
        6.12.5 Kawin Recent Developments/Updates
7 Recombinant Human Granulocyte Colony-Stimulating Manufacturing Cost Analysis
    7.1 Recombinant Human Granulocyte Colony-Stimulating Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating
    7.4 Recombinant Human Granulocyte Colony-Stimulating Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Recombinant Human Granulocyte Colony-Stimulating Distributors List
    8.3 Recombinant Human Granulocyte Colony-Stimulating Customers
9 Recombinant Human Granulocyte Colony-Stimulating Market Dynamics
    9.1 Recombinant Human Granulocyte Colony-Stimulating Industry Trends
    9.2 Recombinant Human Granulocyte Colony-Stimulating Market Drivers
    9.3 Recombinant Human Granulocyte Colony-Stimulating Market Challenges
    9.4 Recombinant Human Granulocyte Colony-Stimulating Market Restraints
10 Global Market Forecast
    10.1 Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Recombinant Human Granulocyte Colony-Stimulating by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Recombinant Human Granulocyte Colony-Stimulating by Type (2023-2028)
    10.2 Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Recombinant Human Granulocyte Colony-Stimulating by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Recombinant Human Granulocyte Colony-Stimulating by Application (2023-2028)
    10.3 Recombinant Human Granulocyte Colony-Stimulating Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Recombinant Human Granulocyte Colony-Stimulating by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Recombinant Human Granulocyte Colony-Stimulating by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables Table 1. Global Recombinant Human Granulocyte Colony-Stimulating Sales Growth Rate Comparison by Type (2022-2028) & (KG) & (US$ Million) Table 2. Global Recombinant Human Granulocyte Colony-Stimulating Sales Growth Rate Comparison by Application (2022-2028) & (KG) & (US$ Million) Table 3. Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Region (US$ Million) (2017 VS 2021 VS 2028) Table 4. Global Recombinant Human Granulocyte Colony-Stimulating Market Competitive Situation by Manufacturers in 2021 Table 5. Global Recombinant Human Granulocyte Colony-Stimulating Sales (KG) of Key Manufacturers (2017-2022) Table 6. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Manufacturers (2017-2022) Table 7. Global Recombinant Human Granulocyte Colony-Stimulating Revenue (US$ Million) by Manufacturers (2017-2022) Table 8. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Share by Manufacturers (2017-2022) Table 9. Global Market Recombinant Human Granulocyte Colony-Stimulating Average Price (USD/g) of Key Manufacturers (2017-2022) Table 10. Manufacturers Recombinant Human Granulocyte Colony-Stimulating Manufacturing Sites and Area Served Table 11. Manufacturers Recombinant Human Granulocyte Colony-Stimulating Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Recombinant Human Granulocyte Colony-Stimulating by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Human Granulocyte Colony-Stimulating as of 2021) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2017-2022) & (KG) Table 16. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2017-2022) Table 17. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2017-2022) & (US$ Million) Table 18. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2017-2022) Table 19. North America Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2017-2022) & (KG) Table 20. North America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2017-2022) Table 21. North America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2022) & (US$ Million) Table 22. North America Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2017-2022) Table 23. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2017-2022) & (KG) Table 24. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2017-2022) Table 25. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2022) & (US$ Million) Table 26. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2017-2022) Table 27. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2017-2022) & (KG) Table 28. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2017-2022) Table 29. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2017-2022) & (US$ Million) Table 30. Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2017-2022) Table 31. Latin America Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2017-2022) & (KG) Table 32. Latin America Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2017-2022) Table 33. Latin America Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2022) & (US$ Million) Table 34. Latin America Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2017-2022) Table 35. Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2017-2022) & (KG) Table 36. Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2017-2022) Table 37. Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2017-2022) & (US$ Million) Table 38. Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2017-2022) Table 39. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2017-2022) & (KG) Table 40. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2017-2022) Table 41. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type (2017-2022) & (US$ Million) Table 42. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Share by Type (2017-2022) Table 43. Global Recombinant Human Granulocyte Colony-Stimulating Price by Type (2017-2022) & (USD/g) Table 44. Global Recombinant Human Granulocyte Colony-Stimulating Sales (KG) by Application (2017-2022) Table 45. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2017-2022) Table 46. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application (2017-2022) & (US$ Million) Table 47. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Share by Application (2017-2022) Table 48. Global Recombinant Human Granulocyte Colony-Stimulating Price by Application (2017-2022) & (USD/g) Table 49. Amgen Corporation Information Table 50. Amgen Description and Business Overview Table 51. Amgen Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 52. Amgen Recombinant Human Granulocyte Colony-Stimulating Product Table 53. Amgen Recent Developments/Updates Table 54. Qilu Pharmaceutical Corporation Information Table 55. Qilu Pharmaceutical Description and Business Overview Table 56. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 57. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Table 58. Qilu Pharmaceutical Recent Developments/Updates Table 59. Shijiazhuang Pharmaceutical Corporation Information Table 60. Shijiazhuang Pharmaceutical Description and Business Overview Table 61. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 62. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Table 63. Shijiazhuang Pharmaceutical Recent Developments/Updates Table 64. Kyowa Hakko Kirin Corporation Information Table 65. Kyowa Hakko Kirin Description and Business Overview Table 66. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 67. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product Table 68. Kyowa Hakko Kirin Recent Developments/Updates Table 69. Gensci Corporation Information Table 70. Gensci Description and Business Overview Table 71. Gensci Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 72. Gensci Recombinant Human Granulocyte Colony-Stimulating Product Table 73. Gensci Recent Developments/Updates Table 74. Amoytop Biotech Corporation Information Table 75. Amoytop Biotech Description and Business Overview Table 76. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 77. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product Table 78. Amoytop Biotech Recent Developments/Updates Table 79. Hangzhou Jiuyuan Corporation Information Table 80. Hangzhou Jiuyuan Description and Business Overview Table 81. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 82. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product Table 83. Hangzhou Jiuyuan Recent Developments/Updates Table 84. Huaxin Corporation Information Table 85. Huaxin Description and Business Overview Table 86. Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 87. Huaxin Recombinant Human Granulocyte Colony-Stimulating Product Table 88. Huaxin Recent Developments/Updates Table 89. Triprime Corporation Information Table 90. Triprime Description and Business Overview Table 91. Triprime Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 92. Triprime Recombinant Human Granulocyte Colony-Stimulating Product Table 93. Triprime Recent Developments/Updates Table 94. Sinovac Corporation Information Table 95. Sinovac Description and Business Overview Table 96. Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 97. Sinovac Recombinant Human Granulocyte Colony-Stimulating Product Table 98. Sinovac Recent Developments/Updates Table 99. Zhaoke Corporation Information Table 100. Zhaoke Description and Business Overview Table 101. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 102. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product Table 103. Zhaoke Recent Developments/Updates Table 104. Kawin Corporation Information Table 105. Kawin Description and Business Overview Table 106. Kawin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022) Table 107. Kawin Recombinant Human Granulocyte Colony-Stimulating Product Table 108. Kawin Recent Developments/Updates Table 109. Production Base and Market Concentration Rate of Raw Material Table 110. Key Suppliers of Raw Materials Table 111. Recombinant Human Granulocyte Colony-Stimulating Distributors List Table 112. Recombinant Human Granulocyte Colony-Stimulating Customers List Table 113. Recombinant Human Granulocyte Colony-Stimulating Market Trends Table 114. Recombinant Human Granulocyte Colony-Stimulating Market Drivers Table 115. Recombinant Human Granulocyte Colony-Stimulating Market Challenges Table 116. Recombinant Human Granulocyte Colony-Stimulating Market Restraints Table 117. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Type (2023-2028) & (KG) Table 118. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Forecast by Type (2023-2028) Table 119. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Type (2023-2028) & (US$ Million) Table 120. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Type (2023-2028) Table 121. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Application (2023-2028) & (KG) Table 122. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Forecast by Application (2023-2028) Table 123. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Application (2023-2028) & (US$ Million) Table 124. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Application (2023-2028) Table 125. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Region (2023-2028) & (KG) Table 126. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Forecast by Region (2023-2028) Table 127. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Region (2023-2028) & (US$ Million) Table 128. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Region (2023-2028) Table 129. Research Programs/Design for This Report Table 130. Key Data Information from Secondary Sources Table 131. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Recombinant Human Granulocyte Colony-Stimulating Figure 2. Global Recombinant Human Granulocyte Colony-Stimulating Market Share by Type in 2021 & 2028 Figure 3. Lenograstim (Granocyte) Product Picture Figure 4. Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim) Product Picture Figure 5. Others Product Picture Figure 6. Global Recombinant Human Granulocyte Colony-Stimulating Market Share by Application in 2021 & 2028 Figure 7. Chemotherapy Induced Neutropenia Figure 8. Before Blood Donation Figure 9. Stem Cell Transplants Figure 10. Others Figure 11. Global Recombinant Human Granulocyte Colony-Stimulating Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Recombinant Human Granulocyte Colony-Stimulating Market Size (2017-2028) & (US$ Million) Figure 13. Global Recombinant Human Granulocyte Colony-Stimulating Sales (2017-2028) & (KG) Figure 14. Recombinant Human Granulocyte Colony-Stimulating Sales Share by Manufacturers in 2021 Figure 15. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Share by Manufacturers in 2021 Figure 16. The Global 5 and 10 Largest Recombinant Human Granulocyte Colony-Stimulating Players: Market Share by Revenue in 2021 Figure 17. Recombinant Human Granulocyte Colony-Stimulating Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 18. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2017-2022) Figure 19. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region in 2021 Figure 20. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2017-2022) Figure 21. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region in 2021 Figure 22. U.S. Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 23. Canada Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 24. Germany Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 25. France Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 26. U.K. Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 27. Italy Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 28. Russia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 29. China Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 30. Japan Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 31. South Korea Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 32. India Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 33. Australia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 34. Taiwan Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 35. Indonesia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 36. Thailand Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 37. Malaysia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 38. Philippines Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 39. Vietnam Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 40. Mexico Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 41. Brazil Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 42. Argentina Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 43. Turkey Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 44. Saudi Arabia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 45. U.A.E Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate (2017-2022) & (US$ Million) Figure 46. Sales Market Share of Recombinant Human Granulocyte Colony-Stimulating by Type (2017-2022) Figure 47. Manufacturing Cost Structure of Recombinant Human Granulocyte Colony-Stimulating Figure 48. Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating Figure 49. Recombinant Human Granulocyte Colony-Stimulating Industrial Chain Analysis Figure 50. Channels of Distribution Figure 51. Distributors Profiles Figure 52. Bottom-up and Top-down Approaches for This Report Figure 53. Data Triangulation Figure 54. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us